Ticagrelor metabolite-M8 D7
| Product Name | Ticagrelor metabolite-M8 D7 |
|---|---|
| Alternate Names | Ticagrelor Stable Isotopes, Stable Isotopes of Ticagrelor |
| CAT No. | CS-O-03658 |
| CAS No. | 220347-05-7 (Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 485.56 g/mol |
| Mol. For. | C₂₁H₁₇D₇F₂N₆O₃S |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Ticagrelor |
| Purity | Not less than 95 % |
| Therapeutic | Anti-Thrombotics |
| Smileys | FC1=C(F)C=CC([C@H]2[C@@H](C2)NC3=NC(SC([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=NC4=C3N=NN4[C@H](C[C@H](O)[C@H]5O)[C@@H]5O)=C1 |
| Canonical Smiles | CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)O)NC4CC4C5=CC(=C(C=C5)F)F |
| InchIKey | XYLIQTKEYHWYGG-XUNGLMTJSA-N |
| Inchl | InChI=1S/C21H24F2N6O3S/c1-2-5-33-21-25-19(24-13-7-10(13)9-3-4-11(22)12(23)6-9)16-20(26-21)29(28-27-16)14-8-15(30)18(32)17(14)31/h3-4,6,10,13-15,17-18,30-32H,2,5,7-8H2,1H3,(H,24,25,26)/t10-,13+,14+,15-,17-,18+/m0/s1 |
| IUPAC | (1S,2R,3S,4R)-4-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]cyclopentane-1,2,3-triol |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Ticagrelor metabolite-M8 D7 is an important chemical entity that plays a vital role in the treatment of cardiovascular diseases. Ticagrelor is an oral antiplatelet agent that is widely used for the prevention of thromboembolic events in patients with acute coronary syndrome. Ticagrelor is metabolized in the liver, and one of its major metabolites is M8 D7. Ticagrelor metabolite-M8 D7 is formed through the oxidation of ticagrelor by cytochrome P450 enzymes.
Ticagrelor metabolite-M8 D7 has been extensively studied for its pharmacological properties and chemical characteristics. It has been found to be a potent inhibitor of platelet aggregation, which is essential in the prevention of thromboembolic events. Ticagrelor metabolite-M8 D7 is also known to have a long half-life, which contributes to its efficacy in the prevention of cardiovascular events.
Chemically, Ticagrelor metabolite-M8 D7 is a structurally complex molecule that contains multiple functional groups, including a carboxylic acid, a lactam, and an amide. It has a molecular weight of 522.6 g/mol and a molecular formula of C26H23ClN6O4. Ticagrelor metabolite-M8 D7 is typically administered orally in the form of tablets or capsules, and its dosage is determined based on the patient's medical condition and response to treatment.
In conclusion, Ticagrelor metabolite-M8 D7 is an important chemical entity that is widely used for the prevention of thromboembolic events in patients with acute coronary syndrome. It is a potent inhibitor of platelet aggregation and has a long half-life, which contributes to its efficacy in the prevention of cardiovascular events. Its chemical properties and pharmacological characteristics make it an important drug in the treatment of cardiovascular diseases.
Get an Instant Quote
Related Compounds
Ticagrelor D4 | Deshydroxyethoxy-2,3-O-(dimethylmethylene) Ticagrelor-d7 | Desethoxyhydroxy Ticagrelor-d7 | Ticagrelor Metabolite-M5 D7 | Ticagrelor D7 |